Differences in RNA processing underlie the tissue specific phenotype of ISCU myopathy  by Sanaker, Petter S. et al.
Biochimica et Biophysica Acta 1802 (2010) 539–544
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbad isDifferences in RNA processing underlie the tissue speciﬁc phenotype of
ISCU myopathy
Petter S. Sanaker a,b, Marina Toompuu a, Vanessa E. Hogan c, Langping He c, Charalampos Tzoulis a,b,
Zoﬁa M.A. Chrzanowska-Lightowlers c, Robert W. Taylor c, Laurence A. Bindoff a,b,⁎
a Department of Clinical Medicine, University of Bergen, Norway
b Department of Neurology, Haukeland University Hospital, N-5021 Bergen, Norway
c Mitochondrial Research Group, Institute for Ageing and Health, The Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, UK⁎ Corresponding author. Department Clinical Med
Haukeland University Hospital, 5021 Bergen, Norway. T
55975165.
E-mail address: laurence.bindoff@nevro.uib.no (L.A.
0925-4439/$ – see front matter © 2010 Elsevier B.V. A
doi:10.1016/j.bbadis.2010.02.010a b s t r a c ta r t i c l e i n f oArticle history:
Received 14 October 2009
Received in revised form 26 February 2010
Accepted 26 February 2010







RNA processingHereditary myopathy with lactic acidosis, or myopathy with exercise intolerance, Swedish type (OMIM
#255125) is caused by mutations in the iron–sulfur cluster scaffold (ISCU) gene. The g.7044GNC ISCU
mutation induces a splicing error in the pre-mRNA that strengthens a weak intronic splice site leading to
inclusion of a new exon and subsequent loss of mRNA and protein. While ISCU is widely expressed,
homozygosity for this particular intronic mutation gives rise to a pure myopathy. In order to investigate
tissue speciﬁcity and disease mechanism, we studied muscle, myoblasts, ﬁbroblasts and blood cells from the
ﬁrst non-Swedish case of this disease. Consistent with the recognised role of ISCU, we found abnormal
activities of respiratory chain complexes containing iron–sulfur clusters in patient muscle. We conﬁrmed
that, in the presence of the g.7044GNC mutation, splicing produces both abnormally and normally spliced
mRNA in all tissues. The ratio of these products varies dramatically between tissues, being most abnormal in
mature skeletal muscle that also has the lowest relative starting levels of ISCU mRNA compared with other
tissues. Myoblasts and ﬁbroblasts have more of the normally spliced variant as well as higher starting levels
of ISCU mRNA. Up-regulation of mtDNA copy number was found in skeletal muscle and myoblasts, but not
ﬁbroblasts, and is thought to represent a compensatory response. Tissue speciﬁcity in this disorder appears
therefore to be dependent on the mRNA starting level, the amount of remaining normally spliced RNA, and
the degree to which compensatory mechanisms can respond.icine, University of Bergen,
el.: +47 55975096; fax: +47
Bindoff).
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Syndromes of exercise intolerance with or without rhabdomyo-
lysis can be caused by a variety of metabolic disorders including those
affecting glycogen [1] and lipid metabolism [2] and mitochondrial
disorders [3,4]. Hereditary myopathy with lactic acidosis was
described by Larsson and Linderholm in ﬁve families from Northern
Sweden in the early 1960s. The disease, which is characterised by
childhood onset exercise intolerance with muscle tenderness and
cramping, dyspnoea and palpitations, is transmitted as an autosomal
recessive trait (OMIM #255125) [5]. It is usually non-progressive,
although two cases of fatal myoglobinuria [6] and some with ﬁxed
muscle weakness [6,7] have been reported.
Recently, two reports concurrently identiﬁed an intronic point
mutation (g.7044GNC, GenBank accession number EU334585) in the
iron–sulfur cluster scaffold (ISCU) gene [8,9] as the cause of thisdisorder. A more severe phenotype has also been described in
compound heterozygous patients having the g.7044GNC together
with an exon 3 missense mutation [7].
The ISCU protein is involved in the assembly of iron–sulfur (FeS)
clusters, essential components of several cellular proteins including
mitochondrial respiratory chain complexes I, II and III and aconitase of
the citric acid cycle [10]. Mitochondrial (ISCU 2) and cytosolic (ISCU 1)
isoforms of ISCU arise from alternative splicing of the ﬁrst exon
yielding two transcript variants (GenBank NM_014301.3 for ISCU 1
and NM_213595.2 for ISCU 2) [11]. The recently described g.7044GNC
mutation in the ISCU gene strengthens a weak splice acceptor site
leading to the inclusion of an abnormal exon, hereafter referred to as
5A between the two last exons 5 and 6, thus affecting both transcript
variants. Inclusion of exon 5A introduces a premature stop codon,
leading to protein truncation by 13 amino acids and was reported to
destabilise the transcript leading to ISCUmRNA depletion [8,9]. While
loss of functional ISCU protein is presumably the cause of the
biochemical defects described, it is not clear why this disease is
clinically restricted to skeletal muscle.
We report the ﬁrst non-Swedish case of this disease in a patient of
Norwegian descent who is homozygous for the g.7044 GNC mutation.
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not only in the patient but also at very low levels in controls. Our
ﬁndings suggest that it is the ratio of normally versus abnormally
spliced intermediate, as well as different steady-state levels of ISCU
transcript and the degree to which tissues can compensate the loss of
ISCU that dictates clinical expression.
2. Materials and methods
2.1. Patient
The patient is currently 25 years old and was born in southern
Norway to non-consanguineous parents. Similar to the Swedish
patients described previously [5], she developed exercise intolerance
in childhood, experiencing shortness of breath, palpitations and
fatigue at low to moderate levels of physical activity. Following
exercise her muscles become tender and swollen. The course has been
variable with periods when she has good physical stamina and is able
to lead a near normal life, to periods when she can barely get out of
bed due to muscle pain and fatigue. Two episodes of documented
rhabdomyolysis required intensive care treatment, and both were
followed by proximal muscle weakness that subsided over a few
weeks. On one of these occasions, CK rose to ∼300000. When
examined in a quiet phase of disease, she had a normal neurological
examination. Resting lactic acidosis (∼4 mM; normal range of 0.4–
1.7 mM) was noted on one occasion, but CK levels were normal.
The patient has had two diagnostic muscle biopsies (ages 15 and
19). In the ﬁrst biopsy, electron microscopy showed some subsarco-
lemmal mitochondrial accumulation, lipid droplet accumulation and
electron dense inclusions in abnormally shaped mitochondria. No
ragged-red or cytochrome c oxidase-deﬁcient ﬁbres were seen in
either biopsy. Histochemical analysis of myophosphorylase and other
glycogen metabolism enzymes studied were normal, as was acylcar-
nitine proﬁle in ﬁbroblasts and CPTII activity in whole muscle. The
patient was referred to our Diagnostic Centre for Mitochondrial
disease for further evaluation, and open skeletal muscle biopsy was
performed under local anaesthesia from vastus lateralis. Tissue
sampling was done as part of the clinical work-up and the subsequent
research project was approved by the Regional Committee forMedical
and Health Research Ethics, University of Bergen, Norway with the
written consent of the patient.
2.2. Muscle sampling and myoblast culture
Skeletal muscle samples for biochemical analysis, RNA and protein
studies were frozen immediately in isopentane pre-chilled in liquid
nitrogen and stored at −80C. Muscle tissue for myoblast culture
collected in cold DMEM was cut into 1 mm×1 mm pieces, left to
adhere on culture plates covered with DMEM growth medium
supplemented with 20% (v/v of DMEM) fetal bovine serum, 1.9 mM
L-glutamine, 1% (v/v of DMEM) chick embryo extract, 79.7 U/ml
penicillin–streptomycin, 0.8 mM pyruvate and 0.16 mM uridine,
mixed 1:1 with sterile ﬁltered conditioned medium (24 h on muscle
derived ﬁbroblasts) and incubated at 37 °C, 5% CO2. Cells growing out
from the explants were harvested around day 14 and subcultured in
pure supplemented growth medium. In order to minimize ﬁbroblast
contamination, cell suspensions were pre-plated on culture dishes for
20 min at each passage and 40 min for the ﬁnal passage before protein
and RNA preparation. Myoblast purity was estimated in parallel
suspensions by ﬂuorescence microscopy and Desmin staining as
described [12], with shorter washes (10 min), and was N90% after
48 h incubation. Cells for biochemical measurements were main-
tained in skeletal muscle cell growth medium kit (Promocell,
Heidelberg, Germany) plus 10% fetal bovine serum, supplemented
with 2.7 mM L-glutamine and 5.38 μg/ml gentamycin. Clonetics®
human skeletal muscle myoblasts in designated growth medium(Lonza, Basel, Switzerland) were used as controls for the myoblast
protein studies and skeletal muscle from non-myopathic patients,
sampled and cultured as described above, were used as controls for
mitochondrial DNA (mtDNA) RNA, one-dimensional Blue-Native (BN)
PAGE and ISCU protein western blotting studies on skeletal muscle
and RNA studies on myoblasts.
2.3. Fibroblast culture
A punch skin biopsy was taken from the patient's upper arm,
trimmed, cut into pieces and incubated in Amniochrome II complete
medium (Lonza, Verviers, Belgium) at 37 °C, 5% CO2. Fibroblasts
growing out from the explant were maintained in DMEM growth
medium with 10% fetal calf serum, 2 mM L-glutamine, 1% non-
essential amino acid solution (Sigma, USA), 100 U/ml penicillin–
streptomycin, 1 mM pyruvate and 0.2 mM uridine. Normal human
dermal ﬁbroblasts (NHDF-p, PromoCell, Heidelberg, Germany),
maintained in designated growth medium, were used as controls for
the protein and RNA studies.
2.4. Respiratory chain function and assembly
Respiratory chain complex activity measurements were per-
formed on mitochondrial fractions from frozen skeletal muscle,
cultured skin ﬁbroblasts and from primary myoblasts as described
[13]. Homogenates of frozen skeletal muscle (20 mg) or cultured
ﬁbroblasts (2×75 cm2 ﬂasks) were prepared for BN PAGE as
described [14] and protein concentrations determined by Bradford
assay. Samples were analysed on 5–15% polyacrylamide gels: for
Western blotting, 40 μg of muscle protein or 60 μg of ﬁbroblast
protein, and for in-gel activity measurement, 75 μg of ﬁbroblast
protein was used. Complex I in-gel activity assay was performed as
described [14], with shortened NADH/NTB incubation time (3 h).
Following electrophoresis, proteins were denatured by incubating
gels 30 min with 1% SDS and 1% ß-mercaptoethanol in water, and
transferred to nitrocellulose membranes. These were blocked in 5%
(w/v) milk/0,1% Tween–TBS (MTTBS) and incubated with primary
antibody (mouse anti-complex I 30 kDa, anti-complex II 70 kDa at
1:1000 and anti-complex IV COX 1 at 1:10,000 dilution (MitoSciences,
Eugene, Oregon, USA) in 5% MTTBS). Rabbit anti-mouse HRP antibody
diluted 1:1000 was used as secondary antibody and signal was
visualised using the ECL Plus kit (GE Healthcare, UK).
2.5. DNA analysis
Total DNA was isolated from blood, cultured cells and skeletal
muscle using QIAmp DNA mini kit (QIAgen, Hilden, Germany). The
ISCUmutation was identiﬁed by sequencing a 637 bp fragment of the
ISCU gene (GenBank accession number NG_011857.1) ampliﬁed by
the following primers, forward 5′-GGTTTGCAACAGTCCTTTTAGATCA
and reverse primer 5′-CCATCGATGCATTAA GGCTAA.
Sequencing of the entire mtDNA was performed as previously
described [4]. Long-range PCR (LPCR) to investigate mtDNA rearran-
gements, and real-time PCR (qPCR) analysis of mtDNA copy number
were performed as described [15]. For themtDNA qPCR study on cells,
pellets remaining after removal of mitochondrial enriched superna-
tant for the biochemical assay were used for DNA extraction.
Homozygosity mapping was performed using the Affymetrix
250K-chip (Affymetrix, Santa Clara, CA, USA).
2.6. ISCU protein studies
Protein extracts were prepared from skeletal muscle by total
protein extraction kit (Chemicon (Millipore), Billerica, MA, USA).
Cultured cells (conﬂuent 25 cm2 ﬂasks) were collected by trypsiniza-
tion, pelleted and lysed in 0.15 M NaCl, 5 mM EDTA pH 8, 1% Triton X-
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aminocaproic acid. Lysates were centrifuged for 10 min at 17,500 g
and protein concentration of the supernatant was determined by
BCA™ protein assay kit (Thermo Scientiﬁc, Waltham, MA, USA). 40 μg
of each sample was denatured in buffer containing 8 M urea, 2% ß-
mercaptoethanol and 5% SDS for 2 h at 37 °C (ﬁnal urea concentration
N2 M), separated on 15% denaturing polyacrylamide gels containing
6 M urea and electroblotted to nitrocellulose membranes. After
blocking in 3% (w/v) milk/ phosphate buffered saline (PBS), these
were incubated with rabbit anti-(full-length) ISCU 1/2 and rabbit
anti-actin, both at 1:200 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) simultaneously, followed by goat anti-rabbit secondary anti-
body incubation (Southern Biotech, Birmingham, AL, USA) and ECL
developing as above.
2.7. RNA studies
Total RNA was extracted from frozen muscle biopsies (∼20 mg)
and cultured cells (conﬂuent 25 cm2 ﬂask) using the Trizol reagent
(Life Technologies, Carlsbad, CA, USA) as recommended by the
manufacturer. RNA was extracted from full blood collected in
PAXgene™ (PreAnalytiX, Switzerland) tube using QIAshredder and
RNeasy Mini Kit (Qiagen, Hilden, Germany). For the splice variants
study, RNA was reverse transcribed with either Superscript II reverse
transcriptase or Multiscribe/TaqMan reverse transcription reagents
(Life Technologies, Carlsbad, CA, USA). In the initial muscle study
Superscript II cDNA was ampliﬁed with the primers 5-F (5′-
GATATCGCCAAGGAGCTCTG) and 6-R (5′-TCATTTCTTCTCTGCCTCTCC)
or 5a-R (5′-GACCAAACTGGAAAGCCAAG) (Fig. 1) under standard
conditions. Subsequent studies were done with Multiscribe cDNA.
After separation on 3% GTG agarose gels, PCR products were puriﬁed
by QIAquick gel extraction kit (Qiagen, Hilden, Germany) andFig. 1. The splicing variants of ISCU in tissues of a patient carrying the g.7044 G≥Cmutation a
5 and 6. The g.7044 GNC mutation (Δ) causes the inclusion of an aberrant exon 5A between
6-R (5′-TCATTTCTTCTCTGCCT CTCC; pos 8290–8310) will amplify a 134 bp fragment (I) in the
234 bp fragment (II) is ampliﬁed. Primers 5-F and (intronic) 5a-R (5′-GACCAAACTGGAAAG
splicing has occurred, and a 630 bp fragment (IV) from the native, unspliced transcript, but
B) RT-PCR on RNA isolated from skeletal muscle from the patient (1,6) and two controls (2,7 a
as well as the aberrant 234 bp product (II), consisting of exons 6+5A+6. In the patien
predominant in both controls (7–8). Intronic reverse primer 5a-R was used (1–4) to amplify
unspliced precursor at 649 bp (IV). The opposite is the case in the controls (2–3). No PCR p
identiﬁed by sequencing. C) Preservation (%) of normal ISCU splicing variant in different ti
proportions (%±SD) of product I to the total amount of spliced transcripts (I+II) in repea
muscle (N=8); 2 — patient myoblast (N=6); 3 — patient ﬁbroblast (N=5); 4 — patient b
7 — myoblast control (N=5); 8 — ﬁbroblast control.sequenced using the same primers shown above on an ABI 3130XL
Genetic Analyzer (Applied Biosystems).
For the ISCU qPCR studies, 100 ng of RNA was reverse transcribed
using the TaqMan reverse transcription reagents (Life Technologies,
Carlsbad, CA, USA). PCR reactions were performed with the Applied
Biosystems 7500 Fast instrument using the TaqMan Gene Expression
Assays (Life Technologies, Carlsbad, CA, USA) for ISCU (Hs00396806_m1),
detecting the exon boundary 4–5 and GAPDH as endogenous control.
Patient skeletal muscle or myoblasts were compared to the average of 3
independent controls. Patient ﬁbroblasts from skin ormuscle originwere
compared to one control for each.3. Results
3.1. Predominant muscle defect of iron–sulfur cluster containing
respiratory chain complexes
Activities of mitochondrial respiratory chain complexes I, II and
III in the homogenate of frozen skeletal muscle were substantially
decreased while the activity of complex IV was normal (Table 1).
One-dimensional Blue-Native polyacrylamide gel electrophoresis
(BN PAGE) followed by Western blotting showed a decreased
amount of complex I in muscle homogenate compared with
controls, but normal levels of complex II (Fig. 2). No abnormal
assembly intermediates of either complex were seen. Biochemical
measurements showed low complex II activity in ﬁbroblasts, but
apart from this, cultured myoblasts and skin ﬁbroblasts had normal
respiratory chain function (Table 1). Similarly, in-gel-activity of
complex I as well as Western blotting of complexes I and II
following BN PAGE was normal in ﬁbroblast mitochondrial fractions
compared with controls (Fig. 2).nd control individuals. A) Cartoon showing the fragment of ISCU gene containing exons
exons 5 and 6. Primers 5-F (5′-GATATCGCCAAGGAGCTCTG; pos 6614-6633 in ISCU) and
presence of a normal junction between exon 5 and exon 6. In the presence of exon 5A, a
CCAAG-3′; pos 7247–7266) will amplify a 261 bp fragment (III) if the aberrant 5 to 5A
will not work on correctly spliced (5 to 6) transcripts due to removal of the 5a-R site.
nd 3,8). Primers 5-F/6-R (5–8) amplify the 134 bp product (I) consisting of exons 5+6,
t (6), the aberrant transcript (II) dominates over the normal transcript (I), which is
the aberrant 5+5A species at 261 bp (III) which, in the patient (1), dominates over the
roducts were observed in negative controls (4–5). (L) — DNA ladder, bp. (*) — species
ssues from our patient and controls. PCR products ampliﬁed using primers 5F/6R. The
ted (N) RT-PCRs, estimated from ethidium bromide ﬂuorescence. 1 — patient skeletal
lood (N=5); 5 and 6 — skeletal muscle controls (N=6+7) (mean value calculated);
Table 1
Mitochondrial respiratory chain complex activities in patient skeletal muscle, cultured ﬁbroblasts and cultured myoblasts.
Sample Muscle Fibroblasts Myoblasts
Patient Controls (n=20) Patient Controls (n=8) Patient Controls (n=4)
Complex I 0.038 0.104±0.036 0.228 0.197±0.034 0.165 0.144±0.045
Complex II 0.032 0.145±0.047 0.112 0.219±0.067 0.270 0.254±0.060
Complex III 0.112 0.554±0.345 0.545 0.646±0.192 ND ND
Complex IV 1.225 1.124±0.511 1.053 1.083±0.186 0.681 0.852±0.224
All activities are expressed as ratios to the activity of citrate synthase. Complex I is expressed as nmol NADH oxidised min−1U citrate synthase−1. Complex II is expressed as nmol
DCPIP reduced min−1U citrate synthase−1. Complex III and complex IV activities are expressed as ﬁrst order rate constants (K s−1unit citrate synthase−1×103). ND: Not done.
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Based on the patient's clinical presentation and biochemical
defects involving mitochondrial respiratory chain complexes contain-
ing iron–sulfur clusters, direct sequencing of the ISCU gene was
undertaken. This showed that our patient was homozygous for the
recently published g.7044GNC ISCU transversion mutation [8,9]. Her
parents were heterozygous (chromatograms in Supplementary
material). Haplotyping showed that the patient is homozygous for a
1.5 Mb region on chromosome 12 containing the ISCU gene (SNP_A-
1661732–SNP_A-1743899) (Supplementary material), comprising
much of the homozygous region found in a previous publication [8].
3.3. ISCU protein is present in lowered amounts in skeletal muscle and
cultured cells
The full-length ISCU 1/2 antibody used for Western blotting is
predicted to identify both the 15 kDa cytoplasmic (ISCU 1) and 14 kDa
mitochondrial isoforms (ISCU 2) [16]. In controls, we identiﬁed only a
single species migrating at approximately 15 kDa. This was clearly
decreased in the patient's muscle homogenate. ISCU levels in patient
myoblasts and skin ﬁbroblasts were also decreased (Fig. 2). Incuba-
tion with an ISCU 1-speciﬁc antibody identiﬁed a band of identical
molecular weight (not shown), suggesting either that the band
detected by the ISCU 1/2 antibody represents the cytoplasmicFig. 2. Levels of mature complex I and ISCU protein in ISCU myopathy patient and controls.
patient (P) and controls (C). Probing with anti-complex I 30 kDa antibody (upper left panel)
patient. Mature complex IV (CIV) (lower left panel) is unaffected in skeletal muscle. In patien
normal. B) In-gel complex I activity. Staining by 3 h incubation with NADH/nitrotetrazolium
with controls (C). C) ISCU protein levels. Western blots after denaturing PAGE probed wi
ﬁbroblasts (FIB) and myoblasts (MYO) in the patient (P) compared to controls (C). (L) Act
220 kDa) (Life Technologies, Carlsbad, CA, USA). Open arrow — ISCU band at ∼15 kDa. Clo
myoblasts, three times for skeletal muscle and ﬁbroblasts).isoform, that the antibody speciﬁcities are sub-optimal or that the
two isoforms have not been sufﬁciently separated by electrophoresis.
A dominant ISCU 1/cytoplasmic ISCU band is contrary to some
previous ﬁndings [16], but corresponds well with the recent study of
Kollberg et al. who found that the major of two ISCU bands present in
whole cell extracts disappeared in the membrane organelle protein
fraction [7]. Both ISCU isoforms should, however, be affected by the
mutation. An additional, faint product running just in front of the
main ISCU band, possibly representing the 13 amino acid truncated
ISCU, was visible in the patient's muscle andmyoblast samples but not
in ﬁbroblasts (Fig. 2).
3.4. Tissues are differently affected by ISCU RNA loss and splicing
abnormalities
The steady-state level of ISCU mRNA estimated by qPCR was
signiﬁcantly decreased in patient myoblasts (20% of controls),
moderately decreased in patient muscle (54% of controls) and
unchanged in patient ﬁbroblasts. In control tissues, the expression of
ISCU relative to a control gene, was 3.5–4-fold higher in cultured cells
than in skeletal muscle. In addition to differences in the steady-state
levels of ISCU transcript, we also observed clear qualitative differences
in the splicing products fromdifferent tissues. Ampliﬁcation of skeletal
muscle cDNA using primers 5-F/6-R (Fig. 1A) showed that the
predominant transcript in the patient contained exons 5+5A+6.A) Blue-Native PAGE on extracts in skeletal muscle (SKM) or ﬁbroblasts (FIB) from the
shows that the level of mature complex I (CI) is low in the skeletal muscle (SKM) of the
t ﬁbroblasts, both complex I (upper right panel) and complex IV (lower right panel) are
blue substrate shows normal complex I activity in the patient's ﬁbroblasts (P) compared
th rabbit anti ISCU 1/2 antibody show loss of ISCU protein in skeletal muscle (SKM),
in loading control. (M) MW ladder (MagicMark™ XP Western Protein Standard) (20–
sed arrow — putative additional ISCU band. The experiment was repeated (twice for
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major bandwas the normally spliced species with exons 5+6 (Fig. 1).
A faint 5+6 band was found in the patient and a band corresponding
by size to the abnormal transcript also seen in the controls, implying, as
has previously been suggested [8], that the mutation does not create a
new splice site, but rather strengthens a pre-existingweak one (Fig. 1).
Bands 5+6 and 5+5A+6 were also detectable in cDNA from
patient myoblasts, ﬁbroblasts and blood (Fig. 1C). The proportion of
correctly spliced transcript (134 bp/134+234) in each sample was
calculated from ethidium bromide ﬂuorescence intensities using Gene
Snap and Gene Tools software (Syngene, Cambridge, UK). Mean
values from replicate PCRs are shown in Fig. 1C. Results from cDNA
generated either by oligo dT or randomhexamer primingwere similar
and were therefore pooled. In patient muscle, approximately 10% of
total transcript appears normally spliced while in controls this species
comprises 90% of the total. In patient's myoblasts, ﬁbroblasts and
blood, both transcripts appear to present in approximately equal
amounts. Similar results were obtained over a wide range of cDNA
concentrations (0.015 ng–0.6 ng/μl PCR reaction).
Using exon primer 5-F and intron primer 5a-R to span the 5–5A
splice junction and subsequent sequencing of PCR products, we found
both the aberrantly spliced transcript and the unspliced precursor in
patient and control muscle, thereby conﬁrming that 5–5A splicing
occurs even in normal skeletal muscle. The abnormally spliced 5–5A
transcript predominates over the native transcript in the patient,
while the reverse is found in control muscle (Fig. 1B). While this PCR
assay seems to yield substantial amounts of the aberrant transcript in
control muscle, this assay analyses mRNA precursors and not mature
mRNA, thus it is the ratio between spliced and unspliced precursor
that is important.
3.5. Mitochondrial DNA is structurally intact, but increased in amount
Whole mitochondrial DNA sequencing revealed only known
polymorphisms [17,18], while LPCR revealed no evidence of mtDNA
rearrangements. Quantitative real-time PCR revealed, however, an
approximate 6-fold increase in the amount of mtDNA in the patient's
skeletal muscle compared with controls, a 17-fold increase in mtDNA
copy number in patient myoblasts, but normal mtDNA levels in both
ﬁbroblasts and blood.
4. Discussion
We report the ﬁrst case of ISCU-deﬁcient hereditary myopathy
with lactic acidosis outside Sweden. Our patient presented with
severe exercise intolerance and rhabdomyolysis, but common causes
including defects of glycogen and fatty acid metabolism were quickly
excluded. Biochemical defects in mitochondrial respiratory chain
complexes I, II and III suggested aberrant iron–sulfur metabolism as a
common denominator; sequencing of the ISCU gene revealed the
previously described g.7044GNC ISCU intronic mutation [8,9]. To
investigate the disease mechanism, particularly why the disorder is
clinically restricted to skeletal muscle, we studied different tissues
from our patient. ISCU has been found to be widely expressed in man,
though highest in heart and skeletal muscle [11].
Our data conﬁrm that the g.7044GNC strengthens an active, but
low-afﬁnity splice site, and that both normal and abnormal transcripts
are detectable in normal tissues. The relative degree to which this
occurs, however, varies between tissues. Using a semi-quantitative
assay, we ﬁnd that the relative amount of abnormal (i.e. that
containing exon 5A) to normal transcript is 10%:90% in control
muscle, but a reverse relationship exists in patient muscle, where 90%
of the transcript is abnormally spliced. Our estimate of approximately
10% remaining normally spliced ISCU RNA correlates well with that
found in an earlier study [8]. In blood cells, cultured ﬁbroblasts andmyoblasts from the patient, 50% ormore of the ISCU transcript appears
to be normally spliced.
In addition to qualitative differences, we also found that the
amount of ISCU RNA varied between mature skeletal muscle and both
types of cultured cell. The relative amount of ISCU RNA was
approximately 4-fold higher in control cells than control skeletal
muscle. In the patient's muscle, the amount of ISCU RNA was
approximately 50% and in myoblasts 20% of control; the level in
ﬁbroblasts was similar to control. Thus, one explanation for the
selective involvement of muscle is the combined effect of quantitative
loss and qualitatively abnormal splicing. Myoblasts appear protected
by having a relatively higher baseline expression and a more normal
splice pattern; based on our ﬁndings, they should have an ∼8-fold
higher relative amount of normally spliced ISCU RNA than muscle.
We show that the amount of ISCU protein is severely decreased in
skeletal muscle; levels are also lower in the patient's myoblasts and
ﬁbroblasts. Inclusion of the aberrant exon 5A, is predicted to yield a
truncated protein lacking an α-helix domain important for function
and similarly to one previous study [7] we identiﬁed a protein
approximately 1.5 kDa smaller than the predominant ISCU band. This
species is present only in muscle and myoblasts from the patient and
not controls (Fig. 2) and based on size, could represent the abnormal
ISCU protein.
In order to examine the consequences of ISCU deﬁciency, we
studied the assembly of respiratory chain complexes containing FeS
centres. There are eight iron–sulfur clusters in complex I, seven of
which are inserted into the peripheral matrix arm involved in linking
NADH oxidation to ubiquinone reduction [19]. Lack of these could
impair complex I assembly. Using antibodies against the 30 kDa
subunit of complex I that is presumed to incorporate into an early
assembly intermediate, we found no stalled intermediates, suggesting
either that assembly only proceeds in the presence of sufﬁcient FeS
clusters or that earlier intermediates are rapidly turned over. BN PAGE
did reveal, however decreased amounts of mature complex I
correlating with the decreased activity suggesting that the deﬁcient
ISCU protein function does lead to complex I deﬁciency. Both in-gel
activity and amount were normal in ﬁbroblasts. Previous studies have
shown low levels of several subunits of complexes I, II and III in
skeletal muscle, but these experiments were performed under
denaturing conditions [20].
Previous studies in a yeast model lacking the iron–sulfur cluster
assembly protein frataxin homologue Yfh1, have clearly shown a loss
of oxidative metabolism and marked depletion of mtDNA [21]. In
addition, aconitase has been reported to play a direct role in mtDNA
maintenance in yeast [22]. In view of these ﬁndings, we investigated
mtDNA copy number and integrity in our patient but found no
evidence of mtDNA rearrangements or mtDNA depletion. Levels of
mtDNA were in fact increased 6-fold in skeletal muscle compared
with controls and even higher in patientmyoblasts (17-fold) although
unchanged in ﬁbroblasts and blood cells. Since these ﬁndings
mirrored the degree to which tissues expressed both phenotypic
and biochemical deﬁciencies, we hypothesise that the increases in
mtDNA levels reﬂect a secondary, compensatory response to some
form ofmitochondrial “stress” induced by ISCUmutation, possibly due
to the accumulation of iron or free radical damage as previously
described in the context of frataxin deﬁciency [23]. Interestingly,
myoblasts manifested a massive up-regulation of mtDNA copy
number suggesting that they are indeed responding to the stress
induced by the ISCU deﬁciency, but are able to cope with this due to
their high baseline ISCU expression and less severe splicing aberration.
In conclusion, our studies conﬁrm that the g.7044 GNC ISCU
mutation strengthens an active, but low-afﬁnity splice site causing
abnormal splicing and the co-occurrence of transcripts with or
without an aberrant exon (exon 5A). We show that the relative
amounts of abnormal to normally spliced ISCU RNA vary between
tissues being most abnormal in skeletal muscle. This, together with a
544 P.S. Sanaker et al. / Biochimica et Biophysica Acta 1802 (2010) 539–544relatively lower starting amount of ISCU transcript suggests that tissue
speciﬁc expression of the ISCUmutation is caused by the combination
of qualitative and quantitative abnormalities.
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